

RISPOVAL RS+PI3 INTRANASAL NASAL SPRAY, LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR CATTLE

Authorised

- Bovine respiratory syncytial virus, strain 375, Live
- Bovine parainfluenza virus 3, strain RLB103, Live

Product identification

Medicine name:

RISPOVAL RS+PI3 INTRANASAL NASAL SPRAY, LYOPHILISATE AND SOLVENT FOR
SUSPENSION FOR CATTLE

Rispoval RS + Pi3 Intranasal Lyophilisat et solvant pour suspension nasale

Active substance:

Bovine respiratory syncytial virus, strain 375, Live

Bovine parainfluenza virus 3, strain RLB103, Live

Target species:

Cattle

Route of administration:

Nasal use

Product details

Active substance and strength:

Bovine respiratory syncytial virus, strain 375, Live
5.00 log10 50% cell culture infectious dose / 1.00 Dose
Bovine parainfluenza virus 3, strain RLB103, Live
5.00 log10 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for nasal administration

Withdrawal period by route of administration:

Nasal use:

-

Cattle

- All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AD07

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Luxembourg

Available in:

Luxembourg

Package description:

Cardboard box with 1 glass vial of 5 doses of powder accompanied by 1 vial containing respectively 10 ml liquid component
Cardboard box with 1 glass vial of 25 doses of powder accompanied by 1 vial containing respectively 50 ml liquid component

Plastic box with 5 glass vial(s) of 1 dose of powder accompanied by 5 vial(s) containing 2 ml liquid component

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

28/08/2006

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Ministry Of Health And Social Security

Authorisation number:

V 087/06/10/0887

Date of authorisation status change:

28/08/2006

Reference member state:

France

Procedure number:

FR/V/0335/001

Concerned member states:

Austria Belgium Bulgaria Czechia Estonia Germany Hungary Ireland Italy
Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia
Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.